Cidofovir dihydrate

Research use only, not for human use.

The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases.

The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases; also incorporates itself into viral DNA hence inhibiting viral DNA synthesis during reproduction.CMV Infection Approved.

Cidofovir (5-100 μM, 72 hours) dihydrate has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cells counts in a dose dependent manner. Cidofovir (10-1000 μM, 24-120 hours) dihydrate can reduce cancer cell viability and induces apoptosis.Cell Cytotoxicity Assay Cell Line:Crandell-Reese feline kidney(CRFK) cellsConcentration:10-100 μM Incubation Time:72 hours Result:Reduced CRFK cells by 9.1%.Cell Viability Assay Cell Line:Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells Concentration:10-1000 μM Incubation Time:24, 48, 72, 96, 120 hours Result:Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group.Apoptosis Analysis Cell Line:FTC-133 cells Concentration:100 μM Incubation Time:96 hours Result:Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.

Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days)dihydrate is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice. Animal Model:Female weanling BALB/c mice infected with cowpox virus (CPV)Dosage:100 mg/kg Administration:Subcutaneous injection; 3-6 days interval; 21 days Result:Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.

HPMPC dihydrate | (S)-HPMPC dihydrate

Microbiology/Virology

CMV

CMV

Infection

CMV Infection

149394-66-1

315.2176

C8H18N3O8P

>98% (HPLC)

10 mM in DMSO

C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O

Phosphonic acid, P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, hydrate (1:2)

(-20℃)

With Ice Pack

≥ 2 years